Zongertinib Earns FDA Accelerated Approval in HER2+ NSCLC
Written by
Cancer Network
Published
0
comments
0
min
Zongertinib is now approved by the FDA for patients with nonsquamous NSCLC with HER2 TKD activating mutations.